RA PHARMACEUTICALS INC's ticker is RARX and the CUSIP is 74933V108. A total of 62 filers reported holding RA PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $2,539,000 | +1.8% | 52,894 | -0.5% | 0.01% | +25.0% |
| Q4 2019 | $2,495,000 | +94.5% | 53,156 | -2.0% | 0.00% | +33.3% |
| Q3 2019 | $1,283,000 | -11.5% | 54,230 | +12.5% | 0.00% | 0.0% |
| Q2 2019 | $1,450,000 | +122.1% | 48,212 | +65.5% | 0.00% | +200.0% |
| Q1 2019 | $653,000 | +59.7% | 29,135 | +29.5% | 0.00% | 0.0% |
| Q4 2018 | $409,000 | +2.2% | 22,498 | +1.8% | 0.00% | 0.0% |
| Q3 2018 | $400,000 | +81.8% | 22,109 | 0.0% | 0.00% | – |
| Q2 2018 | $220,000 | +67.9% | 22,109 | -10.2% | 0.00% | – |
| Q1 2018 | $131,000 | -17.6% | 24,616 | +31.6% | 0.00% | – |
| Q4 2017 | $159,000 | -43.6% | 18,700 | -3.1% | 0.00% | -100.0% |
| Q3 2017 | $282,000 | -27.7% | 19,300 | -7.2% | 0.00% | 0.0% |
| Q2 2017 | $390,000 | +11.1% | 20,800 | +26.1% | 0.00% | 0.0% |
| Q1 2017 | $351,000 | +36.6% | 16,500 | -2.4% | 0.00% | 0.0% |
| Q4 2016 | $257,000 | – | 16,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 6,138,797 | $294,724,000 | 15.40% |
| RA Capital Management | 4,858,260 | $233,245,000 | 7.37% |
| HAVENS ADVISORS LLC | 143,266 | $6,878,000 | 6.70% |
| BARDIN HILL MANAGEMENT PARTNERS LP | 609,614 | $29,267,000 | 6.40% |
| OMNI PARTNERS LLP | 1,052,744 | $50,542,000 | 4.45% |
| HBK INVESTMENTS L P | 2,004,042 | $96,214,000 | 4.03% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,005,600 | $96,289,000 | 3.83% |
| Versor Investments LP | 1,108,845 | $53,236,000 | 3.53% |
| OXFORD ASSET MANAGEMENT LLP | 461,016 | $22,133,000 | 3.12% |
| HighVista Strategies LLC | 63,222 | $3,035,000 | 2.81% |